Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDSNASDAQ:AYTUNASDAQ:ENSC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00$0.00$0.00▼$0.08$5K12.428,169 shs160 shsAYTUAytu BioPharma$1.26+0.8%$1.16$0.95▼$3.45$7.71M-0.129,094 shs12,111 shsENSCEnsysce Biosciences$2.19+0.9%$2.88$1.62▼$14.67$5.19M1.09908,076 shs135,827 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%0.00%0.00%-99.00%-99.83%AYTUAytu BioPharma0.00%-4.57%+20.40%-16.67%-61.77%ENSCEnsysce Biosciences0.00%-15.56%+6.90%-62.59%-72.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAYTUAytu BioPharma1.219 of 5 stars0.03.00.03.41.91.70.6ENSCEnsysce Biosciences0.1567 of 5 stars0.02.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/AAYTUAytu BioPharma 0.00N/AN/AN/AENSCEnsysce Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis Pharmaceuticals$3.09M0.00N/AN/AN/A∞AYTUAytu BioPharma$77.23M0.10N/AN/A$4.64 per share0.27ENSCEnsysce Biosciences$2.23M2.33N/AN/A($3.10) per share-0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/A5/12/2025 (Estimated)AYTUAytu BioPharma-$15.84M-$1.45N/A∞N/A-7.62%-19.30%-4.80%5/14/2025 (Estimated)ENSCEnsysce Biosciences-$10.61M-$13.39N/AN/AN/A-179.26%-292.81%-158.83%N/ALatest AYTU, ARDS, and ENSC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/10/2025Q4 2024ENSCEnsysce Biosciences-$2.74-$2.90-$0.16-$2.90$0.25 million$1.30 million2/12/2025Q2 2025AYTUAytu BioPharmaN/A-$0.28N/A-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AAYTUAytu BioPharmaN/AN/AN/AN/AN/AENSCEnsysce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDSAridis PharmaceuticalsN/AN/AN/AAYTUAytu BioPharma0.320.980.81ENSCEnsysce BiosciencesN/A3.243.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%AYTUAytu BioPharma33.49%ENSCEnsysce Biosciences5.63%Insider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%AYTUAytu BioPharma3.60%ENSCEnsysce Biosciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableAYTUAytu BioPharma1606.17 million6.00 millionNot OptionableENSCEnsysce Biosciences102.37 million1.20 millionNot OptionableAYTU, ARDS, and ENSC HeadlinesRecent News About These CompaniesEnsysce Biosciences Bolsters Management Team with Regulatory ExpertMay 12 at 8:00 AM | accessnewswire.comEnsysce Biosciences (ENSC) Expected to Announce Quarterly Earnings on FridayMay 8, 2025 | americanbankingnews.comEnsysce Biosciences secures patent for OUD treatmentApril 26, 2025 | uk.investing.comEnsysce Biosciences receives U.S. patent for OUD treatmentApril 25, 2025 | markets.businessinsider.comEnsysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross ProceedsApril 24, 2025 | accessnewswire.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsApril 23, 2025 | gurufocus.comEnsysce Biosciences Stock Doubles In One Trading Session - Here's WhyApril 23, 2025 | benzinga.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross ProceedsApril 23, 2025 | accessnewswire.comEnsysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use DisorderApril 23, 2025 | accessnewswire.comEnsysce Biosciences announces data from opioid overdose protection studyApril 17, 2025 | markets.businessinsider.comEnsysce Biosciences files to sell 980,000 shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comENSC Shows Compound Protects Against AbuseApril 15, 2025 | msn.comEnsysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s ThrilledApril 15, 2025 | msn.comEnsysce Biosciences Announces Positive Data from Opioid Overdose Protection StudyApril 15, 2025 | accessnewswire.comEnsysce Biosciences prices 315,188 shares at $3.49 in registered direct offeringApril 1, 2025 | markets.businessinsider.comEnsysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 31, 2025 | accessnewswire.comEnsysce Biosciences Advances in Opioid InnovationMarch 19, 2025 | tipranks.comEnsysce Biosciences announces PAINWeek 2025 SymposiumMarch 18, 2025 | msn.comEnsysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in PainMarch 18, 2025 | accessnewswire.comENSC Starts 2025 in Great ShapeMarch 11, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Can IBM’s Q1 Earnings Spark a Breakout for the Stock?By Jeffrey Neal Johnson | April 23, 2025View Can IBM’s Q1 Earnings Spark a Breakout for the Stock?How to Invest in Micro-Cap Stocks Like a ProBy Dan Schmidt | April 22, 2025View How to Invest in Micro-Cap Stocks Like a ProJoby's Q1: Key Milestones Achieved as Path to Market CrystalizesBy Jeffrey Neal Johnson | May 8, 2025View Joby's Q1: Key Milestones Achieved as Path to Market CrystalizesWaste Management Stock: Tariff Proof, But Overbought?By Chris Markoch | May 2, 2025View Waste Management Stock: Tariff Proof, But Overbought?AYTU, ARDS, and ENSC Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0001 0.00 (0.00%) As of 05/9/2025 10:51 AM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Aytu BioPharma NASDAQ:AYTU$1.26 +0.01 (+0.80%) Closing price 03:39 PM EasternExtended Trading$1.32 +0.06 (+5.08%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Ensysce Biosciences NASDAQ:ENSC$2.19 +0.02 (+0.92%) Closing price 04:00 PM EasternExtended Trading$2.17 -0.02 (-0.91%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
